<DOC>
	<DOCNO>NCT01667289</DOCNO>
	<brief_summary>The purpose study prove superiority concurrent chemoradiation compare radiotherapy alone patient low risk NK/T-cell lymphoma .</brief_summary>
	<brief_title>Radiotherapy Alone Versus Concurrent Chemoradiation Low Risk NK/T-cell Lymphoma</brief_title>
	<detailed_description>Radiotherapy alone commonly use NK/T-cell lymphoma without adverse risk include lymph node involvement , local invasion , B symptoms high LDH level . Recently , methotrexate prove radiosensitizer NK/T-cell lymphoma cell . Therefore , investigator aim verify superiority safety weekly methotrexate combination radiotherapy randomize phase II study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age range 1875 year old Histological confirm , previously untreated stage IE nasal NK/T cell lymphoma without follow risk factor include local invasion , B symptoms high LDH level ECOG performance status 01 Life expectancy 3 month Adequate bone marrow organ function nonnasal NK/Tcell lymphoma Prior exposure methotrexate With third space effusion Pregnant lactate woman Serious uncontrolled disease intercurrent infection History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>NK/T-cell lymphoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Concurrent chemoradiation</keyword>
</DOC>